SVB Leerink reiterated coverage on Xeris Biopharma Holdings with a new price target

2/16/22 5:20:55 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

SVB Leerink reiterated coverage of Xeris Biopharma Holdings with a rating of Outperform and set a new price target of $6.00 from $8.00 previously

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$XERS

Date	Price Target	Rating	Analyst
11/11/2024	$3.00	Overweight → Neutral	Piper Sandler
3/28/2024	$5.00	Outperform	Oppenheimer
8/28/2023	$4.50	Buy	Craig Hallum
10/21/2022	$4.00	Buy	Jefferies
4/28/2022	$6.50	Buy	Craig Hallum
2/16/2022	$8.00 → $6.00	Outperform	SVB Leerink
12/31/2021	$6.00 → $8.00	Outperform	SVB Leerink
12/31/2021	$4.25 → $5.40	Buy	HC Wainwright & Co.